FDA: Don’t Let GDUFA DMF Assessments Delay ANDAs
This article was originally published in The Gold Sheet
Generics manufacturers and their active substance suppliers should take steps to protect ANDAs from delays that new user fee requirements could cause, FDA official says. FDA’s new drug master file (DMF) review team will play a key role in keeping the new DMF completeness assessments from delaying ANDA filings.
You may also be interested in...
US HHS turns to COVID-19 vaccine distributor to assemble vaccine administration kits, citing revised vaccine delivery schedule.
Stand-alone bill headed for Senate, where it fared poorly in coronavirus response legislative packages.
Agency begins gathering manufacturing plant data to prepare for disruptions that can drain inventories over a weekend.